Skip to main content

Matthew B. Laurens, MD, MPH

Academic Title:

Associate Professor

Primary Appointment:

Pediatrics

Secondary Appointment(s):

Medicine

Location:

HSF-I, 480

Phone (Primary):

410-706-5328

Phone (Secondary):

410-706-8695

Fax:

410-706-1204

Education and Training

Oglethorpe University, B.S., Biology, 1992

The Johns Hopkins University Bloomberg School of Public Health, M.P.H., 1996

Mercer University School of Medicine, M.D., 2001

Internship and Residency, Tulane University School of Medicine, Pediatrics, 2001-2004

Chief Residency, Tulane University School of Medicine, Pediatrics, 2004-2005

Fellowship, University of Maryland School of Medicine, Pediatric Infectious Diseases and Tropical Pediatrics, 2005-2008

Biosketch

Dr. Laurens is a pediatric infectious disease specialist with a primary research interest in malaria and antimalarial immunity. He conducts studies at the Center for Vaccine Development (CVD) in Baltimore and at international sites in Burkina Faso, Mali, and Malawi. Dr. Laurens evaluates malaria vaccines and therapeutics, to study the interaction of HIV and malaria and to investigate the acquisition of antimalarial immunity. The broad goal of Dr. Laurens’ research is to illuminate the mechanisms of immunity to malaria with the aim to inform development of malaria vaccines and therapeutics.

Research/Clinical Keywords

Malaria, vaccines, antimalarial immunity, HIV-malaria, Burkina Faso, Mali, Malawi.

Highlighted Publications

Laurens MB, Mungwira RG, Nyirenda OM, Divala TH, Kanjala M, Muwalo F, Mkandawire FA, Tsirizani L, Nyangulu W, Mwinjiwa E, Taylor TE, Mallewa J, Blackwelder WC, Plowe CV, Laufer MK, van Oosterhout JJ. TSCQ Study: A randomized, open-label controlled trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial. Trials. 2016 Jul 18;17:322.

Ishizuka AS, Lyke KE, DeZure A, Berry A, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang L, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Charavarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, KC N, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJM, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson S, Lynn GM, Epstein JE, Kemp M, Gahle GA, Mikolaczak SA, Fishbaugher M, Sack BK, Kappe SHI, Davidson SA, Garver LS, Björkström NK, Nason MC, Graham BS, Roederer M, Sim BKL, Hoffman SL, Ledgerwood JE, Seder RA. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine. 2016 Jun 7;22(6):614-23.

Graves SF, Kouriba B, Diarra I, Daou M, Niangaly A, Coulibaly D, Keita Y, Laurens MB, Berry AA, Vekemans J, Ballou WR, Lanar DE, Dutta S, Heppner DG, Soisson L, Diggs CL, Thera MA, Doumbo OK, Plowe CV, Sztein MB, Lyke KE. Strain-specific Plasmodium falciparum multifunctional CD4+ T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. Vaccine. 2016 May 17;34(23):2546-55.

Lyke KE, Laurens MB, Strauss K, Adams M, Billingsley PF, James E, Manoj A, Chakravarty S, Plowe CV, Li ML, Ruben A, Edelman R, Green M, Sim BKL, Hoffman SL. Optimizing intradermal administration of cryopreserved Plasmodium falciparum sporozoites in controlled human malaria infection. American Journal of Tropical Medicine and Hygiene. 2015 Dec 9;93(6):1274-84.

Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, CummingsJ, Paolino K, Moon J, Komisar J, Kamau E, Oliver T, Chhoeu A, Murphy J, Lyke K, Laurens M, Birkett A, Lee C, Weltzin R, Wille-Reece U, Sedegah M, Hendriks J, Versteege I, Pau MG, Sadoff J, Vanloubbeeck Y, Lievens M, Heerwegh D, Moris P, Guerra Mendoza Y, Jongert E, Cohen J, Voss G, Ballou WR, Vekemans J. Ad35.CS.01 -  RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naïve adult. PLoS One. 2015 Jul 6;10(7):e0131571.

Additional Publication Citations

Travassos MA, Coulibaly D, Laurens MB, Dembélé A, Tolo Y, Koné AK, Traoré K, Niangaly A, Guindo A, Wu Y, Berry AA, Jacobs CG, HarrisonST, Adams M, Shrestha B, Wu AZ, Kouriba B, Lyke KE, Diallo DA, Doumbo OK, Plowe CV, Thera MA. Hemoglobin C trait provides protection from clinical falciparum malaria in Malian children. American Journal of Tropical Medicine and Hygiene. 2015 Jun 3;92(6):1190-4.

Travassos MA, Coulibaly D, Bailey JA, Niangaly A, Adams M, Nyunt MM, Ouattara A, Lyke K, Laurens MB, Pablo J, Jasinkskas A, Nakajima-Sasaki R, Berry AA, Takala-Harrison S, Kone AK, Kouriba B, Rowe A, Doumbo OK, Thera MA, Laufer MK, Felgner PL, Plowe CV. Differential recognition of terminal extracellular Plasmodium falciparum VAR2CSA domains by sera from multigravida, malaria-exposed Malian women. American Journal of Tropical Medicine and Hygiene. 2015 Jun;92(6):1190-4.

Bailey JA, Pablo J, Niangaly A, Travassos MA, Ouattara A, Coulibaly D, Laurens MB, Takala-Harrison S, Lyke KE, Skinner J, Berry AA, Jasinskas A, Nakajima R, Kouriba B, Thera MA, Felgner PA, Doumbo OK, Plowe CV. Seroreactivity to a large panel of field-derived Plasmodium falciparum AMA1 and MSP1 antigen variants reflects seasonal and lifetime acquired antibody responses to malaria. American Journal of Tropical Medicine and Hygiene. 2015 Jan;92(1):9-12.

Coulibaly D, Travassos MA, Kone AK, Tolo Y, Laurens MB, Traore K, Diarra I, Niangaly A, Daou M, Dembele A,  Sissoko M, Guindo B, Douyon R, Guindo A, Kouriba B, Sissoko MS, Sagara I, Plowe CV, Doumbo OK, Thera MA. Stable malaria incidence despite scaling up control strategies in a malaria vaccine testing site in Mali. Malaria Journal. 2014 Sep 19;13:374.

Murphy SC, Hermsen CC, Douglas AD, Edwards NJ, Petersen I, Fahle GA, Adams M, Berry AA, Billman ZP, Gilbert SC, Laurens MB, Leroy O, Lyke KE, Plowe CV, Seilie AM, Strauss KA, Teelen K, Hill AV, Sauerwein RW. External quality assurance of malaria nucleic Acid testing for clinical trials and eradication surveillance. PLoS One. 2014 May 16;9(5):e97398.

Laurens MB, Thera MA, Coulibaly D, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Dube T, Soisson L, Diggs CL, House B, Bennett JW, Lanar DE, Dutta S, Heppner DG Jr, Plowe CV, Doumbo OK. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in Malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS One. 2013 Nov 18;8(11):e79323.

Seder RA, Chang L, Enama ME, Zephir KL, Sarwar UN, Gordon IL, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJM, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja MA, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BKL, Ledgerwood JE, Graham BS, Hoffman SL. Protection against malaria by intravenous immunization with a non-replicating sporozoite vaccine. Science. 2013 Sep 20;341(6152):1359-65.

Travassos MA, Niangaly A, Bailey JA, Ouattara A, Coulibaly D, Laurens MB, Pablo J, Jasinskas A, Nakajima-Sasaki R, Berry AA, Takala-Harrison S, Kouriba B, Rowe JA, Lyke KE, Doumbo OK, Thera MA, Felgner PL, Plowe CV. Seroreactivity to the PfEMP1 intracellular domain in malaria-exposed children and adults. The Journal of Infectious Diseases. 2013 Nov;208(9):1514-1519.

Laurens MB, Billingsley P, Richman A, Eappen AG, Adams M, Li T, Chakravarty S, Gunasekera A, Jacob CG, Sim BKL, Edelman R, Plowe CV, Hoffman SL, Lyke KE. Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: A new model for controlled human malaria infection. PLoS One. 2013 Jul 16;8(7):e68969.

Coulibaly D, Rebaudet S, Travassos M, Tolo Y, Laurens M, Kone AK, Traore K, Guindo A, Diarra I, Niangaly A, Daou M, Dembele A, Sissoko M, Kouriba B, Dessay N, Gaudart J, Piarroux R, Thera MA, Plowe CV, Doumbo OK. Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali. Malaria Journal. 2013 Mar 1;12(1):82.

Ouattara A, Takala-Harrison S, Thera MA, Coulibaly D, Niangaly A, Saye R, Tolo Y, Dutta S, Heppner DG, Soisson L, Diggs CL, Vekemans J, Cohen J, Blackwelder WC, Dube T, Laurens MB, Doumbo OK, and Plowe CV. Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: Vaccine development implications. The Journal of Infectious Diseases. 2013 Feb 1;207(3):511-9.

Boyd MA, Laurens MB, Fiorella PD, Mendley SR. Peritonitis and technique failure caused by Roseomonas mucosa in an adolescent with HIV on continuous cycling peritoneal dialysis. Journal of Clinical Microbiology. 2012 Nov;50(11):3801-4.

Laufer MK, Thesing PC, Dzinjalamala FK, Nyirenda OM, Masonga R, Laurens MB, Stokes-Riner A, Taylor TE, and Plowe CV. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin, or atovaquone-proguanil to treat malaria. PLoS One. 2012 Aug 17;7(8):e42284.

Laurens MB, Duncan CJ, Epstein JE, Hill AV, Komisar JL, Lyke KE, Ockenhouse CF, Richie TL, Roestenberg M, Sauerwein RW, Spring MD, Talley AK, Moorthy VS; The Consensus Group on Design of Clinical Trials of Controlled Human Malaria Infection. A consultation on the optimization of controlled human malaria infection by mosquito bite for the evaluation of candidate malaria vaccines. Vaccine. 2012 Aug 3;30(36):5302-5304.

Shaukat AM, Gilliams EA, Kenefic LJ, Laurens MB, Dzinjalamala FK, Nyirenda OM, Thesing PC, Jacob CG, Molyneux ME, Taylor TE, Plowe CV, Laufer MK. Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment. Malaria Journal. 2012 Jun 18;11(1):207.

Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science. 2011 Oct 28;334(6055):475-480.

Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG Jr, Plowe CV. A field trial to assess a blood stage malaria vaccine. New England Journal of Medicine. 2011 Sep 14;365(11):1004-13.

Lyke KE, Laurens MB, Adams M, Billingsley PF, Richman A, Loyevsky M, Chakravarty S, Plowe CV, Sim KL, Edelman R, Hoffman SL. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: Results of a randomized infectivity trial . PLoS One. 2010 Oct 21;5(10):e13490.

Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, Traore K, Sissoko M, Diallo DA, Diarra I, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara I, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois M, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, Takala SL, Lyke KE, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: Results of a phase 1 randomized controlled trial. PLoS One. 2010 Feb 04;5(2):e9041.

Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BKL. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria . Human Vaccines. 2010 Jan 21;6:97-106.

Research Interests

Dr. Laurens is interested in malaria vaccines, antimalarial immunity, and HIV-malaria coinfection.

Clinical Specialty Details

Pediatric Infectious Disease

Grants and Contracts

Matthew Laurens, M.D. (PI)
Development of Malaria Vaccine Candidate, VLPM01
2/1/16-1/31/17
Maryland Industrial Partnerships Program
Medical Monitor for First-in-human testing of Malaria Vaccine Candidate VLPM01

Miriam Laufer, M.D. (PI)
Matthew Laurens, M.D. (Lead co-investigator, DAIDS CRS lead)
U01AI089342
8/1/11-7/31/18 
National Institutes of Health (NIH)
Clinical Trial of Trimethoprim-sulfamethoxazole or Chloroquine in Adults on ART

  • Clinical trial that will guide Malawi health policy and ultimately affect the health of millions of ART recipients by providing evidence to determine whether to stop TS prophylaxis in person on ART and the importance of preventing HIV-associated opportunistic infections and malaria in persons who are stable on ART.

Claire Fraser, M.D. (PI)
Matthew Laurens, M.D. (Co-investigator)
U19AI110820
4/15/14-3/31/19   
NIH
Host, Pathogen and the Microbiome: Determinants of Infectious Disease Outcome

  • Explore the dynamic interactions between pathogens, hosts, their microbiota, the immune system, and the environment, with the goal to provide a more comprehensive understanding of the determinants of infectious disease outcome.

Karen Kotloff, M.D. (PI)
HHSN272201300022I
8/6/14-9/30/17
NIH/Vaccine and Treatment Evaluation Units (VTEU)
A Phase 1 Challenge Study to Evaluate Safety, Immunogenicity and Efficacy of a Malaria Vaccine (rCSP adjuvanted with GLA-SE), in Healthy Adults, DMID 13-0088

  • First-in-human clinical trial for a candidate malaria vaccine.

Christopher Plowe, M.D. (PI)
Matthew Laurens, M.D. (Protocol Co Principal Investigator)
U01AI112367
1/1/15-12/31/18
NIH                            
Safety and Efficacy of PfSPZ Vaccine in Malaria-Exposed Adults

  • Clinical trial to investigate safety and efficacy of the PfSPZ Vaccine in Burkina Faso, West Africa.

Karen Kotloff, M.D. (PI)
Matthew Laurens, M.D. (Protocol Principal Investigator)
HHSN272201300022I
4/15/15-5/30/17    
NIH/VTEU         
A Phase I Trial to Evaluate the Safety and Infectivity of Direct Venous Inoculation and Intramuscular Injection of Purified, Cryopreserved Plasmodium falciparum (7G8 and NF54) Sporozoites in Non-immune Adults, DMID 14-0040

  • Clinical trial to develop heterologous P. falciparum strains for infectivity studies.

Karen Kotloff, M.D. (PI)
Matthew Laurens, M.D. (Protocol Principal Investigator)
HHSN272201300022I
NIH/VTEU
10/6/15-12/31/16            
Safety, Tolerability, Immunogenicity and Protective Efficacy against Naturally-Transmitted Malaria of Infectious, Cryopreserved Plasmodium falciparum Sporozoites (PfSPZ Challenge) administered by Direct Venous Inoculation under Chloroquine Chemoprophylaxis (PfSPZ-CVac), in Malian Adults: A Randomized, Double Blind, Placebo-Controlled Trial, DMID 15-0052

  • Clinical trial to test PfSPZ-CVac strategy in adults in Mali.

Lab Techniques and Equipment

Dr. Laurens uses malaria microscopy for malaria diagnosis and speciation.

Links of Interest